CA
NZ
UK
AU
IND
US
Splash Beverage Group (NYSE American: SBEV) has entered the pharmaceutical sector with a licensing agreement for CannEpil, an epilepsy treatment. The move reflects a strategic shift for the company as it broadens its business focus beyond beverages into healthcare.
Splash Beverage Group Inc. (NYSE American: SBEV) has entered into an Exclusive License Agreement with Argent Biopharma Limited, acquiring the rights to the pharmaceutical product CannEpil. This product is designed for the treatment of epilepsy and related neurological conditions in humans. The healthcare sector …
Theriva Biologics (NYSE American: TOVX) disclosed on July 7, 2026 that Spain’s Agency of Medicines and Medical Devices granted permission to initiate a Phase IIa trial named VIRAGE2. The study examines a more intensive VCN‑01 dosing schedule alongside standard gemcitabine/nab‑paclitaxel for patients newly diagnosed …
Turn Therapeutics Inc. Is making significant strides in the development of its GX-03 program, which targets atopic dermatitis. On July 7, 2026, the company disclosed a comprehensive strategy for Stage 2 of its Phase 2 clinical trials, aiming to address the growing need for …
MeiraGTx Holdings plc has significantly bolstered its financial resources through a new investment agreement totaling up to $400 million with Oberland Capital. This strategic partnership encompasses a structured credit facility and equity participation designed to expedite the development and commercialization of MeiraGTx's gene therapy …
MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) disclosed on July 6, 2026 that its optimized oral version of SKNY‑1 demonstrated promising pharmacokinetic properties in a series of preclinical studies. The company highlighted the drug’s potential for treating obesity and addiction‑related disorders based on the new data.
Nuvation Bio Inc. (NYSE: NUVB) closed a registered underwritten public offering that generated $287.5 million in gross proceeds.
Oragenics Inc has promoted its Senior Controller to the position of Chief Financial Officer, signaling a strategic move as the healthcare company refines its financial operations. The transition aligns with broader corporate developments, including updated executive compensation and shareholder-approved measures that may influence the …
Omeros Corp. (NASDAQ: OMER) is moving ahead with a debt‑reduction plan that includes buying back $16.0 million of principal tied to its 9.50% convertible notes that mature in 2029. The deal, reached via privately negotiated agreements with certain holders, is slated to close on …
Polomar Health Services Inc. (OTC: PMHS) filed a corporate governance update on July 1, 2026 that reshapes its board composition, senior management, and equity compensation framework. The changes were adopted by unanimous written consent and are intended to support the company’s strategic objectives.
Please wait processing your request...